July 26, 2006 -- GlaxoSmithKline reported its bird flu vaccine produced a strong immune response at a low dose; Pfizer now says it will offer its “good” cholesterol drug as a standalone pill, not just as a combo pill with Lipitor; Alcon received Japanese approval for two eye drugs; Genzyme began treating patients with Gaucher disease in a trial of Genz-112638; Genta settled on a trial design with the FDA for an add-on indication for Genasense; Somaxon claimed positive results from a test of its anti-smoking candidate; New River will exercise its option to co-promote its ADHD drug; Allos received Orphan Drug designation for its lymphoma compound; and Inotek signed a deal worth potentially $625 million with Genentech to develop cancer drugs. The Centient Biotech 200™ rose another 32 points to 3677.51, an advance of .87%. More details...
